JP2004516265A - 強化された微生物阻害を有するプロポフォール製剤 - Google Patents

強化された微生物阻害を有するプロポフォール製剤 Download PDF

Info

Publication number
JP2004516265A
JP2004516265A JP2002550973A JP2002550973A JP2004516265A JP 2004516265 A JP2004516265 A JP 2004516265A JP 2002550973 A JP2002550973 A JP 2002550973A JP 2002550973 A JP2002550973 A JP 2002550973A JP 2004516265 A JP2004516265 A JP 2004516265A
Authority
JP
Japan
Prior art keywords
sterile pharmaceutical
propofol
weight
pharmaceutical formulation
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002550973A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004516265A5 (enExample
Inventor
ザン・ジャック・ヨンフェン
ディン・ジー・フェイ
ルオ・メアリー・ジピン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2004516265A publication Critical patent/JP2004516265A/ja
Publication of JP2004516265A5 publication Critical patent/JP2004516265A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Anesthesiology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2002550973A 2000-12-20 2001-07-16 強化された微生物阻害を有するプロポフォール製剤 Pending JP2004516265A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/745,018 US6399087B1 (en) 2000-12-20 2000-12-20 Propofol formulation with enhanced microbial inhibition
PCT/US2001/022248 WO2002049631A1 (en) 2000-12-20 2001-07-16 Propofol formulation with enhanced microbial inhibition

Publications (2)

Publication Number Publication Date
JP2004516265A true JP2004516265A (ja) 2004-06-03
JP2004516265A5 JP2004516265A5 (enExample) 2005-01-27

Family

ID=24994883

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002550973A Pending JP2004516265A (ja) 2000-12-20 2001-07-16 強化された微生物阻害を有するプロポフォール製剤

Country Status (11)

Country Link
US (1) US6399087B1 (enExample)
EP (1) EP1250130A4 (enExample)
JP (1) JP2004516265A (enExample)
CN (1) CN1359677A (enExample)
AU (1) AU7592501A (enExample)
BR (1) BR0109769A (enExample)
CA (1) CA2397990A1 (enExample)
MX (1) MXPA02008097A (enExample)
RU (1) RU2244545C2 (enExample)
UA (1) UA73970C2 (enExample)
WO (1) WO2002049631A1 (enExample)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013001700A (ja) * 2011-06-21 2013-01-07 Fujifilm Corp プロポフォール含有水中油型エマルション組成物
JP2013006811A (ja) * 2011-06-27 2013-01-10 Fujifilm Corp 容器詰製剤
JP2014501270A (ja) * 2011-01-04 2014-01-20 ノバリック ゲーエムベーハー 部分フッ素化アルカンを含むｏ／ｗエマルション
JP2014510067A (ja) * 2011-03-04 2014-04-24 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング タペンタドールの非経口的投与
JP2019142972A (ja) * 2011-03-04 2019-08-29 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング タペンタドールの非経口的投与
US10898452B2 (en) 2016-09-23 2021-01-26 Gruenenthal Gmbh Stable formulation for parenteral administration of Tapentadol
US11013701B2 (en) 2015-03-27 2021-05-25 Grünenthal GmbH Stable formulation for parenteral administration of tapentadol
US11547678B2 (en) 2011-03-04 2023-01-10 Gruenenthal Gmbh Aqueous pharmaceutical formulation of tapentadol for oral administration

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6749868B1 (en) 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US6979456B1 (en) 1998-04-01 2005-12-27 Jagotec Ag Anticancer compositions
AU759641B2 (en) 1998-08-19 2003-04-17 Skyepharma Canada Inc. Injectable aqueous dispersions of propofol
US20030054042A1 (en) * 2001-09-14 2003-03-20 Elaine Liversidge Stabilization of chemical compounds using nanoparticulate formulations
CA2479665C (en) * 2002-03-20 2011-08-30 Elan Pharma International Ltd. Nanoparticulate compositions of angiogenesis inhibitors
US20080220075A1 (en) * 2002-03-20 2008-09-11 Elan Pharma International Ltd. Nanoparticulate compositions of angiogenesis inhibitors
CA2503956A1 (en) * 2002-10-29 2004-05-13 Transform Pharmaceuticals, Inc. Propofol with cysteine
SI1585548T1 (sl) 2002-12-09 2018-11-30 Abraxis Bioscience, Llc Sestave in metode odmerjanja farmakoloških sredstev
US7468394B1 (en) * 2003-03-11 2008-12-23 Amphastar Pharmaceuticals, Inc. Sterile pharmaceutical composition and process for a solution of propofol emulsion having microbial growth retardation
US20040225022A1 (en) * 2003-05-09 2004-11-11 Desai Neil P. Propofol formulation containing reduced oil and surfactants
US8476010B2 (en) * 2003-07-10 2013-07-02 App Pharmaceuticals Llc Propofol formulations with non-reactive container closures
US8546453B2 (en) * 2003-08-14 2013-10-01 Rensheng Zhang Propofol compositions and methods for reducing pain associated with propofol injection
RU2290169C1 (ru) * 2005-06-23 2006-12-27 Открытое Акционерное Общество "Фаберлик" Косметическое и/или дерматологическое средство и антиоксидант
RU2433818C2 (ru) 2005-08-31 2011-11-20 АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи Композиции, включающие слаборастворимые в воде фармацевтические вещества и противомикробные вещества
NZ592132A (en) * 2005-08-31 2012-12-21 Abraxis Bioscience Llc Composition comprising nanoparticles of docitaxel and a citrate
CN101411685B (zh) * 2007-10-19 2011-04-20 上海医药工业研究院 一种静脉麻醉药2,6-二异丙基苯酚微乳组合物及其制备方法
MX2012010684A (es) 2010-03-17 2012-11-06 Novaliq Gmbh Composicion farmaceutica para el tratamiento de la presion intraocular incrementada.
EP2444063A1 (en) 2010-10-20 2012-04-25 Novaliq GmbH Liquid pharmaceutical compositions for the delivery of active ingredients
EP2462921A1 (en) 2010-11-11 2012-06-13 Novaliq GmbH Liquid pharmaceutical compositions for the treatment of a posterior eye disease
WO2012119729A1 (en) 2011-03-04 2012-09-13 Grünenthal GmbH Semisolid aqueous pharmaceutical composition containing tapentadol
CA2834855C (en) 2011-05-25 2020-12-29 Novaliq Gmbh Topical pharmaceutical composition based on semifluorinated alkanes
PL2806886T3 (pl) 2012-01-23 2017-08-31 Novaliq Gmbh Stabilizowane kompozycje białkowe oparte na semifluorowanych alkanach
MX374014B (es) 2012-05-16 2020-07-24 Mewa Singh Composiciones farmaceuticas para la entrega de farmacos insolubles en agua.
CN113694048B (zh) 2012-09-12 2023-03-24 诺瓦利克有限责任公司 包含半氟化烷烃的混合物的组合物
MX350588B (es) 2012-09-12 2017-09-11 Novaliq Gmbh Composiciones de alcanos semifluorados.
DK3024484T3 (en) 2013-07-23 2018-10-08 Novaliq Gmbh STABILIZED ANTIBODY COMPOSITIONS
WO2017017693A1 (en) * 2015-07-24 2017-02-02 Neon Laboratories Limited Stabilized injectable emulsion of propofol and ketamine
US11622937B2 (en) 2015-08-20 2023-04-11 Mewa Singh Polyphenolic polymer to make water-insoluble molecules become water-soluble
CN120884568A (zh) 2015-09-30 2025-11-04 诺瓦利克有限责任公司 半氟化化合物和其组合物
PL3356313T3 (pl) 2015-09-30 2020-11-16 Novaliq Gmbh 2-perfluoroheksylooktan do podawania okulistycznego
USRE50060E1 (en) 2016-06-23 2024-07-30 Novaliq Gmbh Topical administration method
ES2969758T3 (es) 2016-09-22 2024-05-22 Novaliq Gmbh Composiciones farmacéuticas para usar en la terapia de la blefaritis
CN109906085B (zh) 2016-09-23 2024-03-08 诺瓦利克有限责任公司 含有环孢素的眼用组合物
EP3612228B1 (en) 2017-04-21 2023-08-23 Dermaliq Therapeutics, Inc. Iodine compositions
CN110650734B (zh) 2017-05-12 2024-11-15 诺瓦利克有限责任公司 治疗与隐形眼镜有关病症的包含半氟化烷烃的药物组合物
CA3076776A1 (en) 2017-09-27 2019-04-04 Novaliq Gmbh Ophthalmic compositions comprising latanoprost for use in the treatment of ocular diseases
US11896559B2 (en) 2017-10-04 2024-02-13 Novaliq Gmbh Opthalmic compositions comprising F6H8
AU2019228119A1 (en) 2018-03-02 2020-09-10 Novaliq Gmbh Pharmaceutical compositions comprising nebivolol
CN112153970A (zh) 2018-04-27 2020-12-29 诺瓦利克有限责任公司 用于治疗青光眼的包含他氟前列素的眼用组合物
AU2019358249B2 (en) 2018-10-12 2024-02-22 Novaliq Gmbh Ophthalmic composition for treatment of dry eye disease
US12397039B2 (en) 2019-02-13 2025-08-26 Novaliq Gmbh Compositions and methods for the treatment of ocular neovascularization

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9405593D0 (en) * 1994-03-22 1994-05-11 Zeneca Ltd Pharmaceutical compositions
AU759641B2 (en) * 1998-08-19 2003-04-17 Skyepharma Canada Inc. Injectable aqueous dispersions of propofol
US6140374A (en) * 1998-10-23 2000-10-31 Abbott Laboratories Propofol composition
US6100302A (en) * 1999-04-05 2000-08-08 Baxter International Inc. Propofol formulation with enhanced microbial characteristics

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014501270A (ja) * 2011-01-04 2014-01-20 ノバリック ゲーエムベーハー 部分フッ素化アルカンを含むｏ／ｗエマルション
JP2014510067A (ja) * 2011-03-04 2014-04-24 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング タペンタドールの非経口的投与
JP2018021050A (ja) * 2011-03-04 2018-02-08 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング タペンタドールの非経口的投与
JP2019142972A (ja) * 2011-03-04 2019-08-29 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング タペンタドールの非経口的投与
JP2022033863A (ja) * 2011-03-04 2022-03-02 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング タペンタドールの非経口的投与
US11547678B2 (en) 2011-03-04 2023-01-10 Gruenenthal Gmbh Aqueous pharmaceutical formulation of tapentadol for oral administration
JP2023075244A (ja) * 2011-03-04 2023-05-30 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング タペンタドールの非経口的投与
JP2013001700A (ja) * 2011-06-21 2013-01-07 Fujifilm Corp プロポフォール含有水中油型エマルション組成物
JP2013006811A (ja) * 2011-06-27 2013-01-10 Fujifilm Corp 容器詰製剤
US11013701B2 (en) 2015-03-27 2021-05-25 Grünenthal GmbH Stable formulation for parenteral administration of tapentadol
US10898452B2 (en) 2016-09-23 2021-01-26 Gruenenthal Gmbh Stable formulation for parenteral administration of Tapentadol

Also Published As

Publication number Publication date
RU2244545C2 (ru) 2005-01-20
MXPA02008097A (es) 2004-09-10
CN1359677A (zh) 2002-07-24
BR0109769A (pt) 2003-02-04
UA73970C2 (en) 2005-10-17
WO2002049631A1 (en) 2002-06-27
RU2002122394A (ru) 2004-03-20
US6399087B1 (en) 2002-06-04
EP1250130A1 (en) 2002-10-23
AU7592501A (en) 2002-07-01
EP1250130A4 (en) 2006-03-15
CA2397990A1 (en) 2002-06-27

Similar Documents

Publication Publication Date Title
JP2004516265A (ja) 強化された微生物阻害を有するプロポフォール製剤
US6028108A (en) Propofol composition comprising pentetate
KR100861820B1 (ko) 미생물 특성이 증진된 프로포폴 제제
EP1163007B1 (en) Propofol formulation containing tris
FI120641B (fi) Ruuansulatuskanavan ulkopuolisesti annettavat rasvaemulsiot, jotka sisältävät edetaattia säilöntäaineena
WO2004039326A2 (en) Propofol with cysteine
EP1165046A1 (en) Propofol compositions containing preservative additives
US20070293586A1 (en) Novel propofol composition comprising ascorbic acid or pharmaceutically acceptable salts thereof
AU2001275925B2 (en) Propofol formulation with enhanced microbial inhibition
US20090131538A1 (en) Novel propofol composition comprising a pharmaceutically acceptable salt of formaldehyde sulfoxylate
MXPA01004004A (en) Propofol composition comprising pentetate

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20060926

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20061226

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20070109

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20070612